Chondrosarcoma - A Pipeline Analysis Report

Chondrosarcoma market forecast

Chondrosarcoma is composed of cartilage-producing cells. It is rare cancer that comes under the category of bone and soft tissue tumors known as sarcomas. It has been observed that chondrosarcoma cancer is resistant to both chemotherapy and radiotherapy. In addition, chondrosarcoma can affect an individual at any age. Pain in the back or thigh, sciatica, bladder symptoms, and unilateral edema are some of the symptoms witnessed in patients suffering from chondrosarcoma. According to chondrosarcoma industry analysis, our research analysts have predicted that with the introduction of computerized imaging as one of the most promising approaches to diagnose chondrosarcoma will influence chondrosarcoma market growth in the forthcoming years.

According to the chondrosarcoma industry analysis, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. Our market research analysts have also identified that almost the same amount of drug molecules are in phase I/II and phase II drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase I stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of chondrosarcoma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• Vector Oncology
• Epizyme
• Daiichi Sankyo

Therapeutic assessment of the drug development pipeline for chondrosarcoma by route of administration

• Oral
• Intravenous

The oral route of administration (ROA) involves the administration of drug substances through the mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.

Therapeutic assessment of the drug development pipeline for chondrosarcoma by therapeutic modalities

• Small molecules
• Biologicals

According to this pipeline analysis report, the majority of the molecules that are currently in the drug development pipeline for chondrosarcoma are being developed as small molecules. These molecules are chemically manufactured active substances that bind with specific biological macromolecules and act as an effector and alter the activity of the target cell.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for chondrosarcoma?
• What are the companies that are currently involved in the drug development molecules for chondrosarcoma?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule
• Technavio also offers customization on reports based on specific client requirement.

Technavio also provides customized reports based on the specific requirements of our clients.